Prothena Corp Public (PRTA) FCF Margin (2012 - 2026)
Prothena Corp Public's (PRTA) quarterly FCF Margin came in at 56.53% in Q1 2026, up 194497.0% year-on-year from N/an in Q1 2025, and up 100.05% quarter-over-quarter from 111009.52% in Q4 2025.
Prothena Corp Public (PRTA) FCF Margin (2012 - 2026) Analysis & Trends
Prothena Corp Public's FCF Margin history runs 15 years deep, the most recent figure standing at 56.53% for Q1 2026.
- On a quarterly basis, FCF Margin rose 194497.0% year-over-year to 56.53% in Q1 2026; TTM through Mar 2026 was 140.55%, a 4587.0% decrease from a year earlier, with the FY2025 full-year figure at 1690.6%, down 157936.0% from the prior year.
- FCF Margin improved to 56.53% in Q1 2026 per PRTA's latest filing, from 111009.52% in the prior quarter.
- Across five years, FCF Margin topped out at 56.53% in Q1 2026 and bottomed at 146308.0% in Q1 2024.
- The 5-year median for FCF Margin is 2063.09% (2022), against an average of 17456.34%.
- Across the five-year window, FCF Margin slumped 14411777 bps in 2024 and surged 14441956 bps in 2025, its largest moves.
- Year by year, FCF Margin stood at 10.27% in 2022, then plunged by 161942 bps to 16641.46% in 2023, then jumped by 86 bps to 2252.24% in 2024, then plunged by 4829 bps to 111009.52% in 2025, then soared by 100 bps to 56.53% in 2026.
- Per Business Quant, the three latest PRTA FCF Margin figures stand at 56.53% (Q1 2026), 111009.52% (Q4 2025), and 1680.12% (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.45% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 43.35% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 23.53% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Prothena Corp Public | 458.13 Mn | 128.67 Mn | - | 56.53% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 56.53% |
| Dec 31, 2025 | -111,009.52% |
| Sep 30, 2025 | -1,680.12% |
| Jun 30, 2025 | -1,050.36% |
| Mar 31, 2025 | -1,888.44% |
| Dec 31, 2024 | -2,252.24% |
| Sep 30, 2024 | -4,659.28% |
| Jun 30, 2024 | 11.98% |
| Mar 31, 2024 | -146,308.00% |
| Dec 31, 2023 | -16,641.46% |
| Sep 30, 2023 | 10.69% |
| Jun 30, 2023 | -1,137.05% |
| Mar 31, 2023 | -2,190.23% |
| Dec 31, 2022 | -10.27% |
| Sep 30, 2022 | -2,063.09% |
| Jun 30, 2022 | -2,700.00% |
| Mar 31, 2022 | -3,246.92% |
| Dec 31, 2021 | -1,943.43% |
| Sep 30, 2021 | 80.40% |
| Jun 30, 2021 | 60.96% |